JNJ · News · 20261030N

Segment Revenue Performance

JOHNSON & JOHNSON · 2026-10-30 · Importance 26 · Surprise 24

MedTech accounts for approximately 34% of Johnson & Johnson’s total revenue. In Q3, MedTech performance fell below internal expectations, with international markets—particularly Cardiovascular and Surgery—and continued softness in Abiomed cited as challenges. The article identified orthopedics, surgery, cardiovascular and vision as MedTech markets.

Key facts

• Johnson & Johnson's MedTech segment accounts for approximately 34% of its total revenues. source
• Johnson & Johnson's Innovative Medicine segment was performing strongly. source